Acute myeloid leukemia with pseudo-Chèdiak-Higashi anomaly exhibits a specific immunophenotype with CD2 expression

Am J Clin Pathol. 2006 May;125(5):791-4. doi: 10.1309/93VF-M8CY-06KE-6FD6.

Abstract

Acute myeloid leukemia (AML) with pseudo-Chèdiak-Higashi (PCH) anomaly is a rare morphologic entity. We characterized 5 cases by multiparameter flow cytometry and found that in all cases, the blasts aberrantly expressed CD2, a pan-T cell-associated marker, in addition to their myeloid-associated markers. In contrast, CD2 was expressed in only 25 (17.9%) of 140 cases of newly diagnosed AML without PCH anomaly. CD2 expression correlated strongly with AML with PCH anomaly (P < .01), suggesting a link between a specific immunophenotypic marker, CD2, and AML with PCH anomaly.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / metabolism
  • CD2 Antigens / metabolism*
  • Chediak-Higashi Syndrome / complications
  • Chediak-Higashi Syndrome / drug therapy
  • Chediak-Higashi Syndrome / metabolism
  • Chediak-Higashi Syndrome / pathology*
  • Female
  • Flow Cytometry
  • Humans
  • Immunophenotyping*
  • Karyotyping
  • Leukemia, Myeloid / complications
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / metabolism
  • Leukemia, Myeloid / pathology*
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • CD2 Antigens